CapsoVision clinical leadership transition filing

Rhea-AI Filing Summary

CapsoVision, Inc. reported that Rebecca Petersen plans to retire as Senior Director of Clinical Affairs effective October 15, 2025, and that Keri Jorgenson has been promoted to Director of Clinical Operations to take over responsibility for clinical development operations with the existing team. The company states it does not anticipate any disruption to its clinical development work during this transition. To support a smooth handover, Ms. Petersen will provide consulting services starting October 16, 2025 under an hourly arrangement of $150 per hour, with either party able to terminate the agreement on three days’ notice, and her unvested stock options will continue to vest according to their current schedule.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did CapsoVision (CV) disclose in this 8-K?

CapsoVision disclosed that Rebecca Petersen will retire as Senior Director of Clinical Affairs effective October 15, 2025, and that Keri Jorgenson has been promoted to Director of Clinical Operations to assume responsibility for clinical development operations.

When will Rebecca Petersen’s retirement from CapsoVision (CV) be effective?

Rebecca Petersen’s planned retirement as Senior Director of Clinical Affairs will be effective on October 15, 2025.

What role will Keri Jorgenson have at CapsoVision (CV) after the transition?

Keri Jorgenson has been promoted to Director of Clinical Operations and, along with the clinical operations team, will assume responsibility for CapsoVision’s clinical development operations and activities.

Will Rebecca Petersen continue to work with CapsoVision (CV) after her retirement?

Yes. Starting October 16, 2025, Rebecca Petersen will provide consulting services to CapsoVision and its clinical operations team under a consulting agreement.

How will CapsoVision (CV) compensate Rebecca Petersen under the consulting agreement?

Under the consulting agreement, CapsoVision will pay Rebecca Petersen an hourly rate of $150 per hour for the consulting services she provides.

What happens to Rebecca Petersen’s stock options after her retirement from CapsoVision (CV)?

During her consulting service period, Rebecca Petersen’s currently outstanding unvested employee stock options will continue to vest in accordance with their existing vesting schedule.

Does CapsoVision (CV) expect any impact on its clinical development operations from this leadership change?

CapsoVision stated that it does not anticipate any disruption to its clinical development operations and activities during this transition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/26/2025 - 04:15 PM Learn about SEC filing dates

FALSE000137832500013783252025-09-222025-09-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________________

FORM 8-K

_________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 22, 2025

_________________________

CapsoVision, Inc.

(Exact name of registrant as specified in its charter)

_________________________

Delaware

001-42705

20-3369494

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification Number)

18805 Cox Avenue, Suite 250 Saratoga, California						95070
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s telephone number, including area code: (408)-624-1488

n/a

(Former Name or Former Address, if Changed Since Last Report)

_________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

common stock, $0.001 par value per share

CV

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 22, 2025, Rebecca Petersen notified CapsoVision, Inc. (the “Company”) of her planned retirement as the Company’s Senior Director of Clinical Affairs, effective October 15, 2025. Concurrently, the Company promoted Ms. Keri Jorgenson to Director of Clinical Operations and Ms. Jorgenson, together with the other members of the clinical operations team, will assume responsibility of the Company’s clinical development operations and activities. The Company does not anticipate any disruption to its clinical development operations and activities during this transition. Ms. Jorgenson joined CapsoVision in March 2022 and most recently served as the Company’s Senior Clinical Project Manager, working closely with Ms. Petersen and the Company’s broad, experienced clinical operations team.

To facilitate a smooth transition, Ms. Petersen has agreed to provide consulting services to the Company and the clinical operations team and will enter into a consulting agreement to take effect on October 16, 2025. The Company will pay Ms. Petersen an hourly rate of $150 per hour for the services she provides under the consulting agreement. The consulting agreement may generally be terminated by either the Company or Ms. Petersen upon three days’ notice to the other party. During her service period, Ms. Petersen’s currently outstanding unvested employee stock options will continue to vest in accordance with their existing vesting schedule. The foregoing description of the consulting agreement is qualified in its entirety by reference to the complete text of the consulting agreement, which will be filed with the Company’s Quarterly Report on Form 10-Q for the three months ending September 30, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			CAPSOVISION, INC.
Date: September 26, 2025			By:			/s/ Kang-Huai (Johnny) Wang
			Name:			Kang-Huai (Johnny) Wang
			Title			President and Chief Executive Officer